Jim Tananbaum, MD
Jim has served on the Element Biosciences board of directors since September of 2017. He is the founder and CEO of Foresite Capital, a US-focused healthcare investment firm with $3 billon under management.
Jim has been a lead financier and thought partner for some of the most impactful and fastest growth companies of their generation including: 10x Genomics, Amerigroup (NASDAQ: ANTM), and Jazz Pharmaceuticals (NASDAQ: JAZZ). Jim co-founded and initially ran GelTex Pharmaceuticals (NASDAQ: GENZ) and Theravance (NASD: TBPH and INVA). Jim’s investment experience includes being a co-founder of Prospect Ventures and earlier in his career, a partner of Sierra Ventures, where he established its healthcare services investment practice. Jim has been named to Forbes’ Midas List of Top Tech Investors in four consecutive years from 2015 to 2018.
Jim received his MD and MBA from Harvard, and a Master’s degree from MIT. He graduated with degrees in Applied Math and Electrical Engineering/Computer Science from Yale College.